Physician profile
Nigel E Taylor
NPI 1659602506
$412.19
in general payments reported to CMS, 2019-2025
12 companies · $163 in 2025
The $163 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $32.12 · 2020: $28.68 · 2022: $18.59 · 2023: $63.14 · 2024: $107 · 2025: $163.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $301 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $300.53 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $70.50 | 2024-2025 | |
| Lilly USA, LLC | $58.78 | 2023-2025 | Mounjaro, Trulicity, Zepbound |
| Viiv Healthcare Company | $53.91 | 2023-2024 | Dovato, Apretude |
| Amgen INC. | $51.08 | 2019-2025 | Otezla, Repatha |
| Dexcom, INC. | $34.03 | 2020-2025 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $32.27 | 2025 | Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.82 | 2024 | |
| Astellas Pharma US INC | $21.05 | 2024 | Veozah |
| Abbott Laboratories | $18.59 | 2022 | |
| Merck Sharp & Dohme LLC | $18.05 | 2025 | Capvaxive |
| Glaxosmithkline, LLC. | $17.16 | 2020 | |
| Pfizer INC. | $14.95 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nigel Taylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.